Ruxolitinib (Opzelura) for Atopic Dermatitis
Date: January 24, 2022
Issue #:
1642Summary:
The FDA has approved a 1.5% topical cream
formulation of the Janus kinase (JAK) inhibitor
ruxolitinib (Opzelura– Incyte) for short-term, non-continuous
chronic treatment of mild to moderate
atopic dermatitis (AD) in non-immunocompromised
patients≥12 years old whose disease has not been
adequately controlled with other topical prescription
drugs. Ruxolitinib is the first JAK inhibitor to be
approved for topical use and the first to be approved
in the US for treatment of AD. An oral formulation
of ruxolitinib(Jakafi) is approved for treatment of
myelofibrosis, polycythemia vera, and graft-versus-host
disease.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Atopic dermatitis corticosteroids crisaborole Elidel Eucrisa Jakafi Jakavi Opzelura Pimecrolimus Protopic ruxolitinib Tacrolimus tofacitinib Xeljanz Source Type: research
More News: Corticosteroid Therapy | Dermatitis | Dermatology | Drugs & Pharmacology | Elidel | Prograf | Tacrolimus